This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of interferon beta-1a
MSMED_INTERFERONBETA1A
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
933 |
4. Check minimum number of events
Min. number of events
3
|
933 |
5. Include endpointsNone |
933 |
6. Filter based on genotype QC (FinnGen only) |
856 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of interferon beta-1a
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 856 | 685 | 171 |
| Unadjusted period prevalence (%) | 0.21 | 0.24 | 0.08 |
| Median age at first event (years) | 36.36 | 36.26 | 36.78 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 893
- Matched controls
- 8930
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L03AB07
ATC
interferon beta-1a; parenteral
+∞
307.7
893
*
L04AX07
ATC
dimethyl fumarate; oral
240.0
307.7
218
12
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
8838.6
307.7
864
30
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
893
55
164
Kela drug reimbursment
Fingolimod
333.5
307.7
243
10
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
2022.4
307.7
782
31
109
Kela drug reimbursment
Multiple sclerosis
6050.0
307.7
857
35
N04BB01
ATC
amantadine; oral
95.2
307.7
263
39
H46
ICD-10 Finland
Optic neuritis
137.5
307.7
325
37
L03AX13
ATC
glatiramer acetate; parenteral
397.7
307.7
358
15
N86
ICPC
Multiple sclerosis
284.5
307.7
348
20
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
116.6
307.7
252
30
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
31.1
307.7
555
448
L04AA31
ATC
[U] teriflunomide
220.0
307.7
204
12
M03BX01
ATC
baclofen; systemic
32.1
288.0
195
77
L03AB08
ATC
interferon beta-1b; parenteral
150.7
281.2
140
11
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
28.6
248.0
174
75
TAB00
NOMESCO Finland
Lumbar puncture
14.3
235.2
243
228
353
Kela drug reimbursment
Cladribine and fingolimod
304.4
214.2
210
9
G04BD09
ATC
trospium; oral
37.6
208.8
132
41
L04AA27
ATC
[U] fingolimod
424.0
203.7
197
6
XCK00
NOMESCO Finland
Perimetry
15.2
202.0
194
160
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
33.2
192.0
126
44
XA800
NOMESCO Finland
Neuropsychological investigation
12.1
184.3
207
217
N07XX09
ATC
[U] dimethyl fumarate
249.9
180.6
180
9
XKD06
NOMESCO Finland
Physiologic investigation of micturition
24.4
176.8
130
62
G04BD12
ATC
mirabegron; oral
9.1
162.6
233
334
XKD00
NOMESCO Finland
Uroflowmetry
10.1
153.2
196
243
N06BA07
ATC
modafinil; oral
66.1
152.2
84
14
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.8
135.2
263
519
ZX120
NOMESCO Finland
Intravenous
7.4
129.2
219
374
G04BD04
ATC
oxybutynin; oral, transdermal
11.4
121.2
135
137
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
40.5
115.9
71
19
G04BD07
ATC
tolterodine; oral
12.4
107.8
112
102
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
56.3
102.1
58
11
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
13.8
101.6
98
79
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
7.7
100.9
156
238
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
10.1
98.3
118
132
H02AB04
ATC
methylprednisolone; systemic
5.0
97.7
274
733
TKC22
NOMESCO Finland
Catheterisation instruction
23.3
96.6
71
33
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.6
95.4
308
919
2AB04, ,
NOMESCO Finland
124.9
94.1
100
9
R1250
NOMESCO Finland
Evaluation of functional capability
11.3
92.6
102
101
XKC03
NOMESCO Finland
Water cystometry
12.2
92.4
96
87
N03AE01
ATC
clonazepam; systemic
7.6
91.4
142
217
G04BD08
ATC
solifenacin; oral
8.6
88.6
122
162
UKC02
NOMESCO Finland
Cystoscopy
5.6
87.7
194
421
R20.2
ICD-10 Finland
Paraesthesia of skin
5.4
84.6
195
438
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
309.7
84.2
84
*
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
170.7
75.3
78
5
L04AK02
ATC
teriflunomide; oral
170.7
75.3
78
5
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
74.0
70
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.1
73.8
178
413
L04AE01
ATC
fingolimod; oral
744.9
71.1
69
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
21.2
71.0
54
27
XCD10
NOMESCO Finland
Electrophysiological examination of eye
12.0
67.3
70
63
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.5
65.7
89
115
H53.2
ICD-10 Finland
Diplopia
8.5
61.8
83
106
R4150
NOMESCO Finland
Neuropsychological rehabilitation
15.4
61.8
55
38
G04BD11
ATC
fesoterodine; oral
14.1
61.0
57
43
Z2445
NOMESCO Finland
Psychologist
6.1
60.6
114
210
N03AX12
ATC
[U] gabapentin; oral
3.7
60.4
249
853
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.3
59.2
133
288
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
317.5
59.0
59
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
10.0
58.7
69
74
4AA23, ,
NOMESCO Finland
195.1
53.6
55
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.2
53.4
97
172
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.5
52.6
142
357
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
191.3
52.5
54
*
R33
ICD-10 Finland
Retention of urine
7.1
50.9
80
122
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
12.3
49.3
50
43
L04AG12
ATC
ofatumumab; parenteral
493.0
47.8
47
*
R35
ICD-10 Finland
Polyuria
5.2
47.5
104
219
Z3226
NOMESCO Finland
Physiotherapist
3.2
46.5
237
911
Z3231
NOMESCO Finland
Registered nurse
2.8
44.7
317
1459
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
9.7
44.3
53
58
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
6.9
44.0
70
108
N28
ICPC
Limited function/disability (N)
13.4
42.8
41
32
SPAT1229
SPAT
Assessment of need for aid
5.5
41.3
84
165
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
14.8
41.0
37
26
C10AC01
ATC
colestyramine; oral
6.9
40.5
65
101
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
16.8
40.2
34
21
J01EA01
ATC
trimethoprim; systemic
2.7
39.9
322
1566
R4120
NOMESCO Finland
Occupational therapy
4.1
38.4
115
310
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.2
38.3
109
283
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
15.5
37.5
33
22
RF120, ,
NOMESCO Finland
14.7
37.5
34
24
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
14.2
35.8
33
24
R5110, ,
SPAT
4.0
35.8
109
297
N05CF01
ATC
zopiclone; oral
2.5
35.5
336
1745
TKC20
NOMESCO Finland
Catheterisation of bladder
4.9
34.0
78
170
N03AX16
ATC
[U] pregabalin
2.6
33.5
261
1232
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.8
33.4
112
326
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.9
33.1
184
730
L28
ICPC
Limited function/disability (L)
3.0
33.0
176
683
L04AA40
ATC
cladribine; oral
121.3
32.9
35
*
R4110
NOMESCO Finland
Physiotherapy
2.5
32.6
297
1506
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
6.0
32.0
58
102
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
49.5
31.8
38
8
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.1
31.6
92
242
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
31.4
30
*
XKD03
NOMESCO Finland
Urethral pressure profilometry
7.9
30.8
43
57
N99
ICPC
Neurological disease other
11.0
30.6
33
31
A28
ICPC
Limited function/disability NOS
3.3
30.4
125
415
N29
ICPC
Neurological sympt/complt other
7.4
29.9
44
62
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
107.0
28.8
31
*
N03AF01
ATC
carbamazepine; oral, rectal
4.3
28.7
77
190
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.4
27.2
106
340
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
29.4
25.5
34
12
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
25.5
153
627
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.5
25.5
42
67
G04CA02
ATC
tamsulosin; oral
3.3
25.4
106
354
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.5
24.8
63
149
G50.0
ICD-10 Finland
Trigeminal neuralgia
5.9
24.0
44
78
RF420, ,
NOMESCO Finland
8.3
24.0
32
40
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.2
23.0
96
320
H02AB07
ATC
prednisone; oral
2.6
22.6
147
625
RF410, ,
NOMESCO Finland
8.7
22.0
28
33
Z50.1
ICD-10 Finland
Other physical therapy
4.0
21.9
65
173
U04
ICPC
Incontinence urine
4.2
21.2
58
145
J01CA08
ATC
pivmecillinam; oral
2.0
21.2
475
3278
U02
ICPC
Urinary frequency/urgency
2.4
20.8
158
721
U13
ICPC
Bladder symptom/complaint other
5.3
20.4
42
83
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
24.0
20.0
28
12
A06AD11
ATC
lactulose; oral
2.9
19.9
104
394
N02BF01
ATC
gabapentin; oral
2.6
19.9
134
578
N06AA09
ATC
amitriptyline; systemic
2.8
19.7
104
396
N30.0
ICD-10 Finland
Acute cystitis
2.2
19.5
199
1029
U07
ICPC
Urine symptom/complaint other
3.1
19.2
87
304
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
56.3
19.0
22
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
18.9
237
1325
XF400
NOMESCO Finland
ECG with 12 standard connections
2.6
18.9
126
540
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
18.8
18
*
N06AX16
ATC
venlafaxine; oral
2.2
18.8
200
1051
A02BC02
ATC
pantoprazole; systemic
1.9
18.2
620
4810
H53.1
ICD-10 Finland
Subjective visual disturbances
2.8
17.8
95
364
Z3229
NOMESCO Finland
Other healthcare associate professional
3.0
17.6
81
286
R15
ICD-10 Finland
Faecal incontinence
5.5
17.4
34
64
RS221, ,
NOMESCO Finland
6.2
17.4
30
50
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
14.4
16.9
28
20
L04AX01
ATC
azathioprine; systemic
3.4
16.8
62
191
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
173.1
16.5
17
*
359
Kela drug reimbursment
Mirabegroni
48.4
16.1
19
*
N06AB04
ATC
citalopram; systemic
2.0
15.7
220
1269
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
15.7
15
*
R32
ICD-10 Finland
Unspecified urinary incontinence
5.2
15.6
32
63
3419X
ICD-9 Finland
Other demyelinating diseases of central nervous system, Demyelinating disease of central nervous system, unspecified
162.7
15.5
16
*
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
5.5
15.5
30
56
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
5.5
15.5
30
56
SPAT1231
SPAT
Assessment of adjustments needed in living environment
12.6
15.4
27
22
M03BX02
ATC
tizanidine; oral
1.9
15.4
647
5213
SPAT1216
SPAT
Assessment of functional ability
2.5
15.3
102
436
R42
ICD-10 Finland
Dizziness and giddiness
2.0
15.3
191
1058
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
15.4
14.9
24
16
Z2446
NOMESCO Finland
Social worker
2.8
14.9
80
307
G04BD10
ATC
darifenacin; oral
32.3
14.8
19
6
H47.2
ICD-10 Finland
Optic atrophy
25.5
14.7
20
8
G04CA01
ATC
alfuzosin; oral
3.1
14.6
64
219
34099
ICD-8 Finland
Multiple sclerosis
+∞
14.6
14
*
L04AX09
ATC
diroximel fumarate; oral
+∞
14.6
14
*
N03AF02
ATC
oxcarbazepine; oral
3.5
14.6
51
152
N30.9
ICD-10 Finland
Cystitis, unspecified
2.8
14.5
78
299
L01BB04
ATC
cladribine; systemic
152.4
14.5
15
*
U05
ICPC
Urination problems other
3.6
13.9
46
132
TPH04
NOMESCO Finland
Cathetrisation of vein
2.0
13.9
192
1098
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
11.7
13.8
25
22
G51.0
ICD-10 Finland
Bell palsy
4.2
13.4
36
89
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.2
13.3
117
565
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.2
13.1
119
582
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.1
12.8
55
186
N04BC05
ATC
pramipexole; oral
2.7
12.5
71
280
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
12.5
12
*
36703
ICD-8 Finland
Inflammation of optic nerve and retina, Neuritis optica, retrobulbaris
131.8
12.5
13
*
RS340, ,
NOMESCO Finland
131.8
12.5
13
*
U29
ICPC
Urinary symptom/complaint other
4.0
12.2
35
91
XCK10
NOMESCO Finland
Photography of fundus of eye
2.5
12.0
75
310
KA1AE
NOMESCO Finland
Kidney ultrasound examination
4.5
12.0
29
66
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.3
11.8
94
435
Z43.5
ICD-10 Finland
Attention to cystostomy
30.5
11.7
15
5
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
19.2
11.6
17
9
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.1
11.5
49
165
G04BDXX, ,
ATC
121.5
11.4
12
*
Z2221
NOMESCO Finland
Medical doctor
1.7
11.1
270
1819
G82.2
ICD-10 Finland
Paraplegia, unspecified
28.4
10.7
14
5
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.6
10.5
333
2394
NA7CM
NOMESCO Finland
Spine and spinal cord extensive MRI examination with 3 Tesla magnet
111.3
10.4
11
*
Z01.2
ICD-10 Finland
Dental examination
1.6
10.3
464
3619
U08
ICPC
Urinary retention
8.9
10.3
21
24
A06AC01
ATC
ispaghula (psylla seeds); oral
1.7
10.2
210
1346
J01MA02
ATC
ciprofloxacin; systemic
1.6
10.2
299
2104
U71
ICPC
Cystitis/urinary infection other
2.3
10.2
77
348
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
10.2
10.0
19
19
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
14.8
10.0
16
11
R03CA02
ATC
ephedrine; oral
40.5
10.0
12
*
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
2.3
9.9
79
366
N06AX21
ATC
duloxetine; oral
1.9
9.7
138
790
R39.1
ICD-10 Finland
Other difficulties with micturition
4.3
9.7
25
60
U01
ICPC
Dysuria/painful urination
2.2
9.6
82
391
K59.09
ICD-10 Finland
Constipation, unspecified
2.6
9.5
53
208
ABD40
NOMESCO Finland
Implantation of spinal injection device
+∞
9.4
9
*
A02BA02
ATC
ranitidine; systemic
1.8
9.2
138
804
L89
ICD-10 Finland
Decubitus ulcer and pressure area
7.8
9.2
20
26
OAB43, ,
SPAT
0.6
9.1
282
3774
K59.0
ICD-10 Finland
Constipation
2.8
9.0
46
172
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
2.6
9.0
52
208
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
24.3
8.9
12
5
SPAT1325
SPAT
Vaccination
1.7
8.9
215
1433
H57.9
ICD-10 Finland
Disorder of eye and adnexa, unspecified
4.7
8.9
20
43
H57.1
ICD-10 Finland
Ocular pain
2.4
8.6
57
243
4AA36, ,
NOMESCO Finland
90.9
8.4
9
*
N18
ICPC
Paralysis/weakness
6.8
8.4
20
30
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
2.5
8.4
52
215
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.7
8.3
26
72
119
Kela drug reimbursment
Trigeminal neuralgia or glossofaryngeusneuralgia
14.6
8.2
13
9
U72
ICPC
Urethritis
3.2
8.2
32
103
H04.10
ICD-10 Finland
Dry eye syndrome
1.8
8.0
125
736
H53.4
ICD-10 Finland
Visual field defects
3.9
8.0
23
60
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.6
8.0
220
1510
N02BE01
ATC
paracetamol; systemic, rectal
1.8
8.0
785
7137
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
10.9
7.8
14
13
A02BA04
ATC
nizatidine; systemic
2.5
7.7
50
211
D12
ICPC
Constipation
3.3
7.7
29
91
OAB50, ,
SPAT
2.2
7.7
65
308
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.0
7.5
78
401
N04BD01
ATC
selegiline; oral
7.2
7.5
17
24
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
3.2
7.5
29
93
Z01.8
ICD-10 Finland
Other specified special examinations
1.6
7.4
197
1341
KCW98
NOMESCO Finland
Other transluminal endoscopic operation on bladder
+∞
7.3
7
*
G37.0
ICD-10 Finland
Diffuse sclerosis
+∞
7.3
7
*
G04BE03
ATC
sildenafil; oral
9.5
7.3
14
15
H30.2
ICD-10 Finland
Posterior cyclitis
15.9
7.2
11
7
R30.0
ICD-10 Finland
Dysuria
2.4
7.2
50
218
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.5
7.2
291
2170
Z93.5
ICD-10 Finland
Cystostomy status
30.3
7.2
9
*
N02BF02
ATC
pregabalin; oral
2.1
7.1
72
366
WW400
NOMESCO Finland
Plasmaferesis
20.2
7.1
10
5
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.3
7.0
18
43
NA1CM
NOMESCO Finland
Cervical spine extensive MRI examination with 3 Tesla magnet
13.9
6.9
11
8
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
3.6
6.9
22
62
RF210, ,
NOMESCO Finland
2.8
6.8
33
121
RF432, ,
NOMESCO Finland
40.4
6.8
8
*
N07AA03
ATC
distigmine; systemic
40.4
6.8
8
*
RS222, ,
NOMESCO Finland
6.0
6.6
17
29
C03CA01
ATC
furosemide; systemic
1.8
6.6
110
660
M01AE01
ATC
ibuprofen; systemic, rectal
2.2
6.5
848
7992
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
3.1
6.5
26
85
SFA20
NOMESCO Finland
Two-surface restoration
1.5
6.4
577
4974
G04BD
ATC
Drugs for urinary frequency and incontinence
70.3
6.4
7
*
T83.0
ICD-10 Finland
Mechanical complication of urinary (indwelling) catheter
70.3
6.4
7
*
Z73.6
ICD-10 Finland
Limitation of activities due to disability
8.2
6.3
13
16
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
5.2
6.3
18
35
J01MA06
ATC
norfloxacin; oral
1.7
6.3
111
676
J05AB11
ATC
valaciclovir; oral
1.7
6.3
136
875
CS494
NOMESCO Finland
Other visual field testing
3.5
6.3
21
61
WX320
NOMESCO Finland
Spinalanesthesy
0.5
6.3
74
1290
R19.5
ICD-10 Finland
Other faecal abnormalities
3.9
6.3
18
47
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
18.2
6.3
9
5
R5130, ,
SPAT
26.9
6.2
8
*
RF433, ,
NOMESCO Finland
26.9
6.2
8
*
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
3.7
6.2
19
52
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
3.8
6.1
18
48
J05AB01
ATC
aciclovir; systemic
1.5
6.1
204
1456
G04BD01
ATC
emepronium; systemic
8.7
6.1
12
14
R4110, ,
SPAT
1.7
6.0
103
623
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
145
12
144.06
290.09
2.9
1.3
—
—
—
0
0
214
157
17.61
239.49
1.2
1.1
—
—
—
0
0
207
293
8.89
145.11
1.8
1.5
420.09
0.02
iu/ml
—
5
37
117
69
19.36
144.32
3.8
2.5
1202.10
1315.68
e6/l
0.47
101
63
96
52
20.56
122.81
4.2
2.5
251.21
196.15
e6/l
1.33
81
46
278
651
5.75
117.87
4.2
2.8
9.59
10.39
g/l
3.99
269
607
746
3888
6.58
114.29
16.3
6.3
26.23
29.15
%
12.11
733
3733
777
4213
7.50
113.01
16.9
6.4
1.63
1.96
e9/l
2.67
741
3822
89
51
19.27
110.76
4.1
2.6
405.45
539.40
e6/l
0.95
73
43
777
4273
7.30
109.33
16.9
6.7
0.18
0.18
e9/l
0.17
740
3842
221
506
5.48
94.47
3.6
1.7
0.93
1.35
g/l
4.79
216
478
773
4548
6.21
91.25
17.0
9.5
3.40
3.97
e9/l
15.44
741
4020
57
17
35.75
90.03
1.3
1.1
—
—
—
0
0
77
50
16.76
89.84
3.0
2.1
—
—
—
0
0
372
1412
3.80
80.23
4.5
2.4
4.67
7.83
e6/l
3.99
350
1286
73
60
13.16
74.45
1.2
1.1
1462.71
1638.20
miu/ml
0.46
73
60
453
2111
3.33
68.10
6.6
2.9
17.32
47.81
e6/l
2.67
397
1568
407
1825
3.26
64.47
5.8
2.7
0.12
0.34
e6/l
3.93
342
1291
630
3670
3.43
63.19
2.8
2.5
96.30
75.03
nmol/l
46.80
603
3459
250
1004
3.07
45.35
5.6
2.6
5.20
3.59
e6/l
0.72
138
438
266
1110
2.99
45.03
5.4
2.5
0.96
0.92
e6/l
0.07
155
540
713
4927
3.22
44.91
10.4
3.8
28.80
558.48
e6/l
—
10
56
610
4222
2.40
32.19
7.6
3.3
0.00
0.01
estimate
1.32
142
796
603
4156
2.39
32.08
7.6
3.2
0.01
0.00
estimate
0.38
140
834
605
4197
2.37
31.37
7.6
3.2
0.00
3.48
estimate
0.80
145
838
107
343
3.41
27.47
1.4
1.4
—
—
—
0
0
38
54
7.31
25.60
3.8
2.7
49.19
46.03
%
0.49
26
25
30
6
51.63
25.38
1.2
1.2
—
—
—
0
0
531
3818
1.96
20.88
5.2
6.2
9.53
10.23
umol/l
1.56
516
3640
62
171
3.82
19.85
1.4
2.9
2.55
1.95
index
0.33
29
89
649
7555
0.48
19.09
3.3
3.8
1.22
1.26
mmol/l
0.73
605
7233
717
7963
0.49
14.33
3.8
4.4
1.51
1.50
mmol/l
0.34
659
7666
108
494
2.35
13.94
6.6
2.2
0.18
0.35
e6/l
0.65
103
467
723
7984
0.50
13.28
3.9
4.5
4.82
4.84
mmol/l
0.21
678
7720
22
21
10.71
11.80
2.4
2.2
2.47
1.61
ratio
0.81
22
21
734
8029
0.52
11.68
4.2
4.8
2.86
2.89
mmol/l
0.47
679
7738
313
2177
1.67
11.44
9.0
3.3
0.00
0.00
estimate
1.08
144
807
158
926
1.86
10.40
1.9
2.0
28.87
29.24
s
0.46
153
901
285
1974
1.65
10.39
2.3
1.4
1.98
2.21
g/l
2.14
208
1335
675
5772
1.69
10.19
6.0
7.7
73.57
74.58
u/l
0.35
643
5537
116
626
1.98
9.76
2.5
2.1
4988.74
5499.92
u/l
0.04
36
261
343
2521
1.59
9.65
7.4
2.6
0.01
0.09
estimate
0.59
130
699
414
3283
1.49
7.69
8.5
3.0
0.01
0.03
estimate
1.03
122
704
879
8375
4.16
7.65
20.5
10.5
26.81
26.26
u/l
0.56
872
8242
59
285
2.15
6.70
1.8
1.6
—
—
—
0
0
842
7918
2.11
6.47
15.1
12.2
19.87
19.71
mg/l
0.05
654
6333
24
75
3.26
6.46
1.0
1.1
—
—
—
0
0
6
0
+∞
6.26
1.5
0.0
—
—
—
0
0
18
51
3.58
5.62
1.2
3.5
20.92
14.74
index
0.68
13
35
117
1748
0.62
5.49
1.2
1.3
1.65
9.81
u/ml
6.21
52
768
364
2945
1.40
5.49
3.9
3.3
28.51
29.44
u/l
0.30
353
2827
807
7551
1.71
5.37
13.9
10.7
95.71
90.91
ml/min/173m2
12.15
738
6878
22
75
2.98
5.17
1.2
1.3
0.99
0.57
ratio
1.58
12
39
141
971
1.54
4.90
1.9
1.8
—
—
—
0
0
480
4141
1.34
4.53
4.0
4.6
6.04
6.39
mmol/l
5.27
452
3855
139
1921
0.67
4.42
1.3
1.4
10.68
24.59
iu/ml
7.62
33
585
25
100
2.54
4.41
1.0
1.1
—
—
—
0
0
40
197
2.08
4.40
1.4
1.5
11.52
13.52
e6/l
0.12
29
149
361
3004
1.34
4.27
4.2
4.9
37.23
37.17
g/l
0.08
341
2874
673
6146
1.39
4.21
5.2
3.2
41.70
38.76
u/l
0.45
654
5953
818
7759
1.65
4.17
13.7
12.4
139.89
139.67
mmol/l
2.30
811
7638
40
203
2.02
4.08
1.5
1.6
440.83
146.73
e6/l
0.54
29
161
819
7778
1.64
4.06
13.7
12.6
3.89
3.92
mmol/l
2.48
806
7636
51
282
1.86
4.06
7.5
2.4
1.02
1.02
ratio
0.05
40
260
104
700
1.55
4.00
1.9
1.7
—
—
—
0
0
46
248
1.90
3.96
1.3
1.4
28.02
25.00
u/l
0.24
36
205
13
35
3.75
3.60
1.1
4.0
1.00
0.74
index
0.72
13
35
348
2941
1.30
3.51
1.8
1.9
100.15
98.40
pmol/l
0.26
180
1613
25
112
2.27
3.51
1.0
1.1
—
—
—
0
0
685
7295
0.74
3.48
4.0
5.0
36.19
37.71
mmol/mol
7.73
641
7027
700
7428
0.73
3.44
3.7
4.2
5.58
5.71
mmol/l
2.35
642
7080
99
684
1.50
3.40
1.9
1.8
—
—
—
0
0
123
890
1.44
3.35
2.4
2.6
4.39
5.94
umol/l
2.01
106
768
249
2048
1.30
3.00
2.2
2.1
133.04
146.06
u/l
0.23
241
1964
29
533
0.53
2.96
1.1
1.1
0.86
0.89
g/l
0.36
29
533
105
1423
0.70
2.92
1.6
1.9
3.21
3.42
ratio
1.15
77
1075
29
524
0.54
2.81
1.1
1.1
1.64
1.57
g/l
0.73
29
524
789
7533
1.41
2.74
6.2
5.6
1.66
1.74
mu/l
1.46
754
7247
14
56
2.52
2.54
2.3
3.0
51.18
56.57
%
0.38
14
51
10
31
3.25
2.52
1.5
2.6
—
—
—
0
0
17
76
2.26
2.45
1.1
1.1
137.76
114.47
pmol/l
0.60
17
76
0
63
0.00
2.43
0.0
1.1
—
8.67
—
0
63
184
2221
0.78
2.27
4.5
3.4
8.25
8.08
mmol/l
0.19
161
1965
97
727
1.37
2.20
2.2
2.5
51.00
39.27
u/l
0.28
77
604
27
459
0.58
2.16
1.5
1.7
4.54
3.65
mg/l
0.21
16
330
21
111
1.91
2.02
1.4
1.3
—
—
—
0
0
21
111
1.91
2.02
1.4
1.3
—
—
—
0
0
11
44
2.52
2.01
1.1
1.1
—
—
—
0
0
82
1088
0.73
2.01
1.3
1.7
3.47
3.50
mmol/l
0.07
57
749
8
27
2.98
1.94
1.1
1.1
92.75
97.93
%
—
8
27
97
1247
0.75
1.93
1.8
1.8
1.43
1.39
%
0.24
92
1130
34
521
0.64
1.82
1.2
1.5
—
—
—
0
0
212
1810
1.22
1.79
8.2
3.3
1.02
1.87
kg/l
0.50
155
1186
207
1767
1.22
1.75
1.6
1.5
20.07
20.59
nmol/l
0.20
179
1582
323
2879
1.19
1.73
5.2
6.1
1.22
1.22
mmol/l
0.07
296
2705
5
13
3.86
1.71
1.0
1.6
44.78
45.46
g/l
—
5
13
163
1936
0.81
1.71
5.5
4.1
8.85
8.81
mg/mmol
0.00
109
1212
15
75
2.02
1.70
1.1
1.5
—
—
—
0
0
106
843
1.29
1.65
1.4
1.6
1095.49
1185.58
nmol/l
0.26
82
672
328
3636
0.85
1.65
2.5
2.7
—
—
estimate
—
0
0
18
98
1.85
1.62
1.1
1.3
—
—
—
0
0
143
1192
1.24
1.52
3.0
3.2
729.32
267.55
ng/l
0.53
82
670
26
404
0.63
1.51
1.7
1.9
—
—
—
0
0
29
186
1.58
1.50
1.7
2.1
187.59
247.33
ug/l
0.27
29
171
41
575
0.70
1.45
2.1
2.4
87.69
76.60
ml/min/173m2
0.83
16
244
361
3288
1.16
1.44
6.1
6.7
1.21
1.21
mmol/l
0.09
308
2879
20
326
0.60
1.43
1.5
1.7
—
—
—
0
0
421
4542
0.86
1.43
2.9
3.2
99.44
83.36
ug/l
0.97
398
4363
619
6486
0.85
1.42
3.7
3.7
—
—
—
0
0
10
46
2.19
1.40
1.2
1.4
—
—
—
0
0
13
67
1.95
1.38
2.7
1.9
19.29
40.80
mg/l
—
7
45
693
7190
0.84
1.38
27.4
15.4
332.46
332.70
g/l
0.37
693
7154
19
114
1.68
1.29
1.2
1.6
—
—
—
0
0
25
167
1.51
1.13
2.0
6.9
—
201.04
—
0
23
92
1101
0.82
1.06
1.8
2.0
—
—
—
0
0
9
46
1.97
1.03
1.3
1.7
—
78.20
%
—
0
5
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
9
46
1.97
1.03
1.0
1.1
—
—
—
0
0
5
22
2.28
1.03
1.2
1.5
—
—
—
0
0
5
22
2.28
1.03
1.2
1.5
—
—
—
0
0
64
794
0.79
1.03
1.3
1.6
1081.95
1030.14
mu/l
0.21
55
641
93
776
1.22
1.02
5.2
6.9
105.22
104.55
mmol/l
0.92
93
776
5
107
0.46
1.01
1.2
1.1
—
—
—
0
0
66
532
1.26
0.99
2.7
3.7
1.82
1.77
mmol/l
0.04
59
461
21
140
1.51
0.98
1.6
3.3
—
2605.27
—
0
11
27
376
0.71
0.97
1.7
2.1
6.12
6.99
ug/l
0.13
22
349
12
197
0.60
0.94
1.1
1.2
—
—
—
0
0
20
290
0.68
0.91
1.5
1.4
0.53
0.42
nmol/l
0.24
14
238
57
460
1.26
0.87
1.2
1.3
163.00
234.18
miu/ml
0.82
21
236
86
1013
0.83
0.87
1.3
1.4
31.84
25.91
iu/l
0.81
76
880
6
30
2.01
0.87
1.5
1.5
—
—
—
0
0
6
30
2.01
0.87
1.5
1.5
—
—
—
0
0
39
301
1.31
0.84
1.8
2.8
0.66
0.63
%
0.25
39
301
74
880
0.83
0.83
1.7
1.9
—
—
—
0
0
170
1888
0.88
0.82
1.8
2.3
295.72
313.60
umol/l
1.69
156
1730
56
682
0.81
0.80
5.4
5.3
—
—
—
0
0
29
384
0.75
0.80
1.3
1.6
—
—
—
0
0
19
131
1.46
0.79
1.3
2.0
—
2186.67
—
0
6
9
53
1.71
0.75
1.8
1.2
—
—
—
0
0
105
916
1.17
0.75
2.0
2.5
24.86
24.02
%
0.26
95
862
9
54
1.67
0.74
1.4
2.2
1.21
1.19
mmol/l
—
9
54
9
55
1.64
0.73
1.4
2.2
106.44
105.78
mmol/l
—
9
55
5
25
2.01
0.72
6.8
2.3
0.50
1.88
%
—
5
25
41
327
1.27
0.71
1.2
1.3
—
—
—
0
0
42
520
0.80
0.71
1.3
1.5
—
—
—
0
0
117
1319
0.87
0.71
1.8
2.6
131.62
97.54
ug/g
0.34
83
1066
18
251
0.71
0.70
1.2
1.2
—
—
—
0
0
126
1123
1.14
0.68
2.1
2.5
15.29
14.48
umol/l
0.53
118
1056
47
571
0.81
0.68
1.6
1.7
289.51
298.05
mu/l
0.09
41
516
605
5858
1.10
0.68
3.2
4.1
9.44
9.20
mm/h
0.20
581
5598
35
439
0.79
0.67
1.2
1.5
0.89
0.97
ratio
1.44
22
271
35
439
0.79
0.67
1.2
1.5
1.25
1.18
ratio
0.15
22
271
35
439
0.79
0.67
1.2
1.5
1.08
1.13
ratio
0.17
22
271
57
477
1.21
0.66
3.8
4.0
78.08
81.36
ng/l
0.10
49
443
35
438
0.79
0.66
1.2
1.4
—
—
—
0
0
16
224
0.71
0.64
1.4
1.4
269.89
314.88
ug/g
—
7
121
34
269
1.27
0.64
1.1
1.1
2.30
3.94
—
5
44
27
209
1.30
0.61
1.6
1.8
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
24
186
1.30
0.55
1.0
1.1
10.66
17.86
au/ml
—
5
63
44
523
0.83
0.54
1.6
1.5
—
—
—
0
0
19
248
0.76
0.52
1.2
1.2
—
—
—
0
0
9
136
0.66
0.51
1.4
1.5
—
—
—
0
0
17
127
1.35
0.50
4.4
3.4
24.48
22.30
mg/l
—
10
89
7
109
0.64
0.48
1.3
1.2
12.49
12.49
u/l
—
7
92
323
3384
0.93
0.48
1.8
1.9
1.32
1.40
mmol/l
0.86
267
3012
22
277
0.79
0.47
1.4
1.5
46.12
57.82
ug/l
1.51
22
277
46
535
0.85
0.46
1.5
1.4
—
—
—
0
0
12
163
0.73
0.44
1.1
1.3
—
—
—
0
0
35
294
1.20
0.43
3.2
2.2
5.62
4.33
iu/l
0.38
17
126
9
130
0.69
0.43
5.4
2.6
8.36
8.34
kpa
—
9
130
253
2400
1.08
0.43
3.2
2.8
36.20
61.33
ng/l
0.29
143
1212
112
1025
1.11
0.43
2.1
2.4
2.45
2.42
g/l
0.34
105
959
17
131
1.30
0.42
1.0
1.2
—
14.67
—
0
9
114
1240
0.91
0.42
2.1
2.3
2.42
2.42
mmol/l
0.39
101
1118
22
176
1.26
0.42
1.6
1.6
—
—
—
0
0
18
228
0.79
0.41
2.2
3.0
1.15
1.30
mg/l
0.61
18
211
44
508
0.86
0.41
3.1
4.7
4.46
16.48
ug/l
0.69
37
393
0
15
0.00
0.41
0.0
1.0
—
0.13
—
0
10
0
15
0.00
0.41
0.0
1.6
—
1.19
—
0
15
73
654
1.13
0.41
3.8
3.8
4.48
4.55
pmol/l
0.32
66
595
11
79
1.40
0.41
1.6
1.2
—
—
—
0
0
0
17
0.00
0.40
0.0
1.4
—
—
—
0
0
16
123
1.31
0.40
1.2
3.3
0.95
2.01
ratio
—
9
70
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
43
495
0.86
0.39
1.5
1.5
—
—
—
0
0
242
2300
1.07
0.39
1.3
1.3
0.76
1.71
u/ml
1.71
58
686
87
790
1.11
0.39
5.2
6.4
1.00
1.04
mmol/l
0.77
82
743
23
187
1.24
0.39
1.4
1.4
170.00
166.71
au/ml
—
7
54
21
169
1.25
0.39
1.3
1.9
0.00
0.00
g/l
-0.00
21
159
5
37
1.35
0.37
1.2
1.1
—
—
—
0
0
5
37
1.35
0.37
1.2
1.4
—
—
—
0
0
5
37
1.35
0.37
1.2
1.2
—
—
—
0
0
31
364
0.85
0.37
5.3
3.2
5.05
5.17
kpa
0.40
31
354
24
288
0.83
0.36
1.5
1.4
69.20
114.01
pmol/l
0.55
24
281
5
79
0.63
0.35
1.2
2.0
—
—
—
0
0
27
227
1.20
0.35
1.9
2.0
—
—
—
0
0
20
163
1.23
0.34
2.1
2.7
—
—
—
0
0
19
154
1.24
0.34
1.4
1.8
0.00
0.00
g/l
-0.00
19
148
176
1859
0.93
0.34
2.0
2.2
2.41
2.65
mg/l
0.75
149
1653
12
91
1.32
0.34
1.2
1.4
—
—
—
0
0
245
2343
1.06
0.34
2.2
2.6
51.94
58.46
u/l
1.84
233
2218
54
603
0.89
0.33
2.1
2.5
0.60
0.64
ug/l
0.26
32
278
26
219
1.19
0.33
1.2
1.3
—
40.68
—
0
6
6
86
0.70
0.33
3.2
1.6
0.66
1.21
promille
—
6
68
7
52
1.35
0.31
1.7
2.9
794.86
647.19
u/ml
—
7
52
84
774
1.09
0.31
4.1
3.9
30.31
31.82
%
0.60
64
580
13
164
0.79
0.31
1.0
1.1
—
—
—
0
0
16
196
0.81
0.30
1.2
1.2
—
—
—
0
0
21
249
0.84
0.29
1.0
1.1
0.43
1.61
u/ml
—
9
119
13
103
1.27
0.28
2.6
2.9
6.22
7.14
mmol/l
1.26
13
98
11
85
1.30
0.28
1.4
1.6
—
—
—
0
0
223
2140
1.06
0.28
1.6
1.6
—
—
—
0
0
16
193
0.83
0.27
1.5
2.2
4.52
5.12
umol/l
—
9
145
19
225
0.84
0.26
1.0
1.1
1.53
2.58
u/ml
—
10
105
11
86
1.28
0.26
1.4
1.6
—
—
—
0
0
11
86
1.28
0.26
1.4
1.6
—
—
—
0
0
32
362
0.88
0.26
1.7
1.8
—
—
—
0
0
15
123
1.22
0.25
1.3
1.8
—
—
—
0
0
24
207
1.16
0.25
1.5
1.6
—
—
—
0
0
10
78
1.29
0.24
1.8
1.2
—
—
—
0
0
33
370
0.89
0.24
1.2
1.3
11.52
11.08
u/l
0.07
27
304
17
201
0.84
0.24
5.8
3.1
24.47
24.69
mmol/l
0.11
17
191
72
773
0.93
0.23
2.6
3.3
22.04
21.99
%
0.01
25
245
5
38
1.32
0.23
1.2
1.4
—
—
—
0
0
15
178
0.84
0.22
1.4
1.4
—
—
—
0
0
5
41
1.22
0.22
1.2
1.3
—
—
—
0
0
22
252
0.87
0.22
1.1
1.1
3.24
4.65
u/ml
0.41
11
129
0
10
0.00
0.21
0.0
10.7
—
5.75
—
0
10
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
1.17
—
0
12
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
654
6612
0.96
0.20
5.1
4.8
14.38
14.32
pmol/l
0.30
610
6316
9
113
0.79
0.20
1.6
1.4
—
—
—
0
0
6
51
1.18
0.19
1.0
1.1
77.88
154.49
iu/ml
—
6
51
52
482
1.08
0.19
2.9
3.1
1.23
1.23
mmol/l
0.04
44
419
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
118
1.19
0.19
1.8
4.4
0.32
0.34
iu/ml
—
5
55
10
81
1.24
0.19
1.8
1.2
—
—
—
0
0
6
53
1.13
0.18
1.2
1.4
—
—
—
0
0
12
143
0.84
0.18
1.0
1.3
—
—
—
0
0
102
972
1.06
0.18
3.0
3.6
1.31
1.40
ug/l
0.29
92
896
11
91
1.21
0.17
1.3
1.4
—
—
—
0
0
24
268
0.89
0.17
1.1
1.3
73.46
44.62
u/ml
—
5
26
35
320
1.10
0.17
2.1
2.8
77.28
86.56
ng/l
0.16
29
280
36
330
1.09
0.17
1.7
1.5
—
—
—
0
0
64
602
1.07
0.17
7.7
10.0
0.76
0.75
mmol/l
0.01
47
492
15
129
1.17
0.17
3.3
2.8
1.21
1.39
mmol/l
0.45
15
122
5
69
0.72
0.17
1.2
2.1
—
—
—
0
0
108
1126
0.95
0.16
2.6
3.4
0.84
0.82
mmol/l
0.85
103
1083
10
83
1.21
0.15
1.8
1.2
—
—
—
0
0
10
83
1.21
0.15
1.8
1.2
—
—
—
0
0
20
178
1.13
0.15
1.3
1.1
0.65
2.59
eliau/ml
—
6
94
13
150
0.86
0.14
3.6
2.4
7.49
7.15
pmol/l
0.05
13
150
188
1932
0.97
0.14
1.6
1.7
0.58
0.83
mg/l
2.83
141
1466
7
87
0.80
0.14
1.0
1.1
—
—
—
0
0
150
1548
0.96
0.14
1.8
2.0
—
—
—
0
0
41
439
0.93
0.14
1.4
1.6
0.20
0.32
mg/l
1.40
17
189
22
200
1.10
0.12
1.3
1.7
—
—
—
0
0
22
200
1.10
0.12
1.2
1.3
354.67
242.35
u/ml
1.05
12
131
26
282
0.92
0.12
1.2
1.1
1.28
2.01
u/ml
0.27
12
141
166
1702
0.97
0.12
1.9
2.1
—
—
—
0
0
15
134
1.12
0.11
1.7
3.7
24.53
32.31
umol/l
2.08
15
125
21
229
0.92
0.11
1.2
1.4
—
—
—
0
0
12
106
1.13
0.10
4.2
2.1
18.24
17.05
%
0.59
12
106
250
2460
1.02
0.09
2.5
3.3
2.34
2.35
mmol/l
0.17
229
2295
10
87
1.15
0.09
1.8
1.2
—
—
—
0
0
5
48
1.04
0.09
1.0
1.1
18.92
51.90
u/ml
—
5
48
135
1319
1.03
0.09
2.2
2.8
596.36
617.22
ng/l
0.04
110
1070
6
57
1.05
0.08
1.0
1.1
—
—
—
0
0
7
64
1.09
0.08
1.6
1.2
6.99
5.92
umol/l
—
7
58
15
164
0.91
0.08
2.6
1.9
—
—
—
0
0
221
2243
0.98
0.08
1.6
1.7
—
—
—
0
0
6
71
0.84
0.07
1.0
1.4
69.83
70.94
umol/l
—
6
71
57
550
1.04
0.07
1.1
1.1
—
—
—
0
0
10
112
0.89
0.07
1.1
1.2
17.60
15.96
u/ml
—
5
53
179
1819
0.98
0.07
2.1
2.1
—
—
—
0
0
7
84
0.83
0.07
1.4
1.5
37.70
30.56
nmol/l
—
7
67
13
118
1.10
0.07
1.4
1.5
—
—
—
0
0
15
163
0.92
0.07
1.2
1.2
1.20
3.91
u/ml
—
5
56
17
158
1.08
0.06
1.2
1.3
—
—
—
0
0
135
1371
0.98
0.05
1.5
1.6
447.45
48395296.42
pmol/l
2.22
123
1246
35
363
0.96
0.04
1.7
1.7
45.49
9.71
u/ml
—
9
111
11
101
1.09
0.04
1.7
1.2
—
—
—
0
0
87
855
1.02
0.04
1.4
1.3
194.71
151.47
u/ml
0.30
35
348
31
299
1.04
0.04
1.1
1.3
3.18
15.04
u/ml
—
5
54
16
167
0.96
0.01
1.3
1.3
2.00
5.41
u/ml
—
6
66
20
196
1.02
0.00
1.4
1.6
—
—
—
0
0
43
426
1.01
0.00
1.6
2.3
3.08
6.91
iu/ml
—
8
110
46
456
1.01
0.00
1.6
1.8
—
—
—
0
0
75
745
1.01
0.00
1.3
1.3
178.86
205.40
u/ml
0.12
69
692
11
107
1.03
0.00
2.1
2.0
—
—
—
0
0
60
599
1.00
0.00
2.6
2.6
—
—
—
0
0
10
101
0.99
0.00
1.4
1.4
—
—
—
0
0
12
119
1.01
0.00
1.0
1.2
—
—
—
0
0
25
247
1.01
0.00
2.4
2.4
8.70
10.45
mg/l
0.75
25
232
16
155
1.03
0.00
1.4
1.4
—
—
—
0
0
12
115
1.04
0.00
1.4
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
7.13
—
0
7
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
1.75
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
0.00
—
0
6
5
59
0.85
-0.00
1.0
1.1
—
—
—
0
0
8
83
0.96
-0.00
1.5
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
53
0.94
-0.00
2.0
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
30.00
—
0
6
5
57
0.88
-0.00
1.0
1.4
7.20
6.41
u/l
—
5
49
8
81
0.99
-0.00
5.5
3.6
17.50
47.93
u/ml
—
8
81
7
76
0.92
-0.00
2.3
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
291.40
—
0
5
5
49
1.02
-0.00
1.0
1.8
2.30
3.40
mg/l
—
5
49
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
13.44
—
0
5
8
83
0.96
-0.00
1.5
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
12.5
—
10.11
—
0
8
8
82
0.98
-0.00
1.5
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
79
1.01
-0.00
1.1
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
11.72
—
0
5
7
79
0.89
-0.00
1.0
1.1
293.00
292.59
mg/l
—
7
74
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_INTERFERONBETA1A – Use of interferon beta-1a
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).